Vancomycin-resistant enterococci, colonizing the intestinal tract of patients in a university hospital in Greece

Brazilian Journal of Infectious Diseases

Volumn 10, Issue 3, 2006, Pages 179-184

  Metallidis, Simeon ^a   Chatzidimitriou, Maria ^a   Tsona, Afroditi ^a   Bisiklis, Alexandros ^a   Lazaraki, Georgia ^a   Koumentaki, Eleni ^a   Gikas, Ahilleas ^b   Alexiou Daniel, Stela ^a   Nikolaidis, Pavlos ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b Technological Institute of Heraklion   (Greece)

Author keywords

Hospitalized patients; Inestinal tract; Vancomycin resistant enterococci

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; IMIPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; UREIDOPENICILLIN DERIVATIVE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM CARRIER; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENTEROCOCCUS CASSELIFLAVUS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; EPIDEMIOLOGICAL DATA; FACTORIAL ANALYSIS; FECES ANALYSIS; FEMALE; GREECE; HEALTH SURVEY; HOSPITAL INFECTION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; INTESTINE INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT ASSESSMENT; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; UNIVERSITY HOSPITAL; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CROSS INFECTION; ENTEROCOCCUS; FECES; FEMALE; GREECE; HOSPITALS, UNIVERSITY; HUMANS; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; RISK FACTORS; VANCOMYCIN RESISTANCE;

EID: 33749076892     PISSN: 14138670     EISSN: 14138670     Source Type: Journal    
DOI: 10.1590/S1413-86702006000300005     Document Type: Article

References (37)

1. Spera, R.V., Farber B.F. Multiply resistant Enterococcus faecium: the nosocomial pathogen of the 1990s. JAMA 1992;26:2563-4.
2. Emori T.G., Gaynes R. P. An overview of nosocomial infections, including the role of the microbiology laboratory. Clinical Microbio Reviews 1992;6:428-42.
3. Chenoweth C., Schaberg D.R. The epidemiology of enterococci. Eur J Clin Microbiol Infect Dis 1990;9:80-90.
4. Moellering R.C. Emergence of enterococcus as a significant pathogen. Clin Inf Dis 1992; 14:1173-8.
5. Leclercq R., Derlot E., Duval J., Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in E. faecium. New England. J Medicine 1988;319:157-61.
6. Kaplan R.R., Gilligan P.H., Facklam R.R. Recovery of resistant enterococci during vancomycin prophylaxis. J Clin Microbiol 1988;26:1216-8.
7. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States 1989-1993. Morbidity and Mortality Weekly Report 1992;42:597-600.
8. Tsakris A., Pournaras S., Douboyas J. Changes in antimicrobial resistance of enterococci isolated in Greece. J Antimicrob Chemother 1997;40:735-7.
9. Facklam R R., Collins M.D. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 1989;27:731-4.
10. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa, 1993.
11. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility tests, 4th ed. Approved standards. NCCLS document M7-A2. National Committee for Clinical Laboratory Standards, Villanova, Pa, 1990.
12. Chavers L.S., Moser S.A., Benjamin W.H., et al. Vancomycin resistant enterococci: 15 years and counting. J Hosp Inf 2003;53:159-71.
13. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999. Amer J Inf Control 1999;27:520-32.
14. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001. Amer J Inf Control 2001;29:404-21.
15. Nosocomial enterococci resistant to vancomycin United States, 1989-1993. Morbidity and Mortality Weekly Report 1993;42:597-9.
16. Edmond M.B., Ober J.F., Dawson J.D., et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:1234-9.
17. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Amer J Medicine 1998;104 (suppl):S7-10.
18. Staphylococcus aureus resistant to vancomycin-United States, 2002. Morbidity and Mortality Weekly Report 2002;51: 565-567.
19. Antonios N. Maniatis, Spyros Pournaras, Maria Kanellopoulou, et al. Dissemination of Clonally Unrelated Erythromycin and Glycopeptide-Resistant Enterococcus faecium Isolates in a Tertiary Greek Hospital. J Clin Microbiol 2001; 39(12):4571-4.
20. Schouten M.A., Hoogkamp-Korstanje J.A.A., Meis F.G., A. Voss and the European VRE Study Group. (2000). Prevalence of Vancomycin-Resistant Enterococci in Europe. Eur J Clin Microbiol Inf Dis 2000;19:816-22.
21. Endtz H.P., N. Van den Braak, A. Van Belkum, et al. Buitting, A. Van Duin, and H. A. Verbrugh. Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands. J Clin Microbiol 1997; 35:3026-31.
22. Boisivon A., Thibault M., Leclercq R. Colonization by vancomycin-resistant enterococci of the intestinal tract of patients in intensive care units from French general hospitals. Clin Microbiol Inf 1997;3:175-9.
23. Gordts B., Van Landuyt H., Ieven M., et al. Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients. J Clin Microbiol 1995;33:2842-6.
24. Wells C.L., Juni B.A., Cameron S.B., et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995;21:45-50.
25. Boyle J.F., Sournakis S.A., Rendo A., et al. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993;31:1280-5.
26. Handwerger S., Raucher B., Altarac D., et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin and gentamicin. Clin Inf Dis 1993;16:750-5.
27. Edmond M.B., Ober J.F., Weinbaum D.L., et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995;20:1126-33.
28. Montecalvo M.A., Horowitz H., Gedris C., et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994;38:1363-7.
29. McDonald L.C., Kuehnert M.J., Tenover F.C., Jarvis W.R. Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications. Emerg Infect Dis 1997;3:311-7.
30. Woodford N., Johnson A.P., Morrison D., et al. Current perspectives on glycopeptide resistance. Clin Microbiol Rev 1993;8:585-615.
31. Bates J., Jordens Z., Selkon J.B. Evidence for an animal origin of vancomycin-resistant enterococci. Lancet 1993;342:490-1.
32. Donnelly J.P., Voss A., Witte W., Murray B.E. Does the use of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans? J Antimicrob Chemother 1996;37:389-90.
33. Chadwick P.R., Woodford N., Kaczmarski E.B., et al. Glycopeptide-resistant enterococci isolated from uncooked meat. J Antimicrob Chemother 1996;38:908-9.
34. Torres C.J.A., Reguera M.J., Sanmartin J.C., et al. Van-A mediated vancomycin resistant Enterococcus spp. in sewage. J Antimicrob Chemother 1994;33:553-61.
35. Montecalvo M.A., Horowitz H., Gedris C., et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994;38:1363-7.
36. Roghmann M.C., McCarter R.J., Brewrink J., et al. Clostridium difficile infection is a risk factor for bacteremia due to vancomycin- resistant enterococci (VRE) in VRE-colonized patients with acute leukemia. Clin Infect Dis 1997;25:1056-9.
37. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1995;44:1-12.